GlassScriptPhysician profile
Jeffrey A Punim
NPI 1962467258
$4,336.34
in general payments reported to CMS, 2019-2025
22 companies · $230 in 2025
The $230 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,451 · 2020: $561 · 2021: $650 · 2022: $160 · 2023: $855 · 2024: $430 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,514.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $596.62 | 2019-2024 | Evenity, Prolia |
| Mannkind Corporation | $558.75 | 2019-2023 | Afrezza |
| Lilly USA, LLC | $551.69 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $346.30 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.93 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Novo Nordisk INC | $241.44 | 2019-2021 | |
| Abbvie INC. | $196.85 | 2019-2024 | |
| Abbott Laboratories | $175.07 | 2019-2023 | Freestyle Libre 3 |
| Insulet Corporation | $166.94 | 2019-2023 | Omnipod |
| Recordati_rare_diseases_inc. | $155.13 | 2024 | Isturisa |
| Amarin Pharma, INC. | $133.41 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $124.12 | 2019-2023 | |
| Kyowa Kirin, INC. | $121.83 | 2025 | |
| Cequr Corporation | $118.83 | 2022 | |
| Corcept Therapeutics | $117.60 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $107.71 | 2025 | Yorvipath |
| Dexcom, INC. | $97.70 | 2023 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $94.05 | 2020 | |
| Ibsa Pharma INC. | $39.79 | 2019 | |
| Merck Sharp & Dohme LLC | $32.37 | 2019 | |
| Medtronic, INC. | $18.23 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Punim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.